Article citationsMore>>

Kochanek, M., Schalk, E., von Bergwelt-Baildon, M., Beutel, G., Buchheidt, D., Hentrich, M., Henze, L., Kiehl, M., Liebregts, T., von Lilienfeld-Toal, M., Classen, A., Mellinghoff, S., Penack, O., Piepel, C. and Boll, B. (2019) Management of Sepsis in Neutropenic Cancer Patients: 2018 Guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology, 98, 1051-1069.
https://doi.org/10.1007/s00277-019-03622-0

has been cited by the following article:

• TITLE: Non-Neutropenic Sepsis in Cancer Patients: The Luminal Obstruction Syndrome

  AUTHORS: Tamás Kullmann, Dóra Füzi, Tamás Pintér

  KEYWORDS: Sepsis, Biliary Sepsis, Urosepsis, Bronchogenic Sepsis, Solid Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.10 No.10, September 29, 2019

  ABSTRACT: Background: Neutropenic sepsis is a frequent complication of cytotoxic chemotherapy delivered for cancer patients. Its management is well determined by clinical guidelines. Non-neutropenic sepsis is another potential complication in cancer patients. Its management is less established in the medical literature. Materials and Methods: Three cases are presented to illustrate favourable evolution of non-neutropenic biliary-, uro- and bronchogenic-sepsis in cancer patients with poor prognosis. Results: All three patients had a survival over six months after the management of the septic complication. Two of them received subsequent systemic anticancer treatment. Conclusions: Survival benefit offered by the management of cancer-related non-neutropenic sepsis may be comparable to the benefit obtained by systemic anticancer treatments. Cost-effectiveness of sepsis management may be better than that of anticancer treatments.